Chemotherapeutic Nanoparticle-Based Liposomes Enhance the Efficiency of Mild Microwave Ablation in Hepatocellular Carcinoma Therapy

Overview

Journal Front Pharmacol

Date 2020 Mar 17

PMID 32174827

Citations 9

Authors

Songsong Wu

Dongyun Zhang

Jie Yu

Jianping Dou

Xin Li

Mengjuan Mu

Ping Liang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer, and the 5-year overall survival (OS) rate for HCC remains unsatisfying worldwide. Microwave ablation (MWA) is a minimally invasive therapy that has made progress in treating HCC. However, HCC recurrence remains problematic. Therefore, combination therapy may offer better outcomes and enhance MWA efficiency through improved tumor control. We have developed doxorubicin-loaded liposomes (DNPs) as an efficient nanoplatform to enhance MWA of hepatocellular carcinoma even at the mild ablation condition. In this study, we demonstrated that the uptake of DNPs by HCC cells was increased 1.5-fold compared with that of free DOX. Enhanced synergism was observed in the combination of DNPs and MWA, which induced nearly 80% cell death. The combination of mild MWA and DNPs enhanced the ablation efficiency of HCC with significant inhibition of liver tumors and accounted for the longest survival rate among all groups. A much higher accumulation of the DNPs was observed in the transitional zone than in the ablation zone. No apparent systemic toxicity was observed for any of the treatments after 14 days. The present work demonstrates that DNPs combined with MWA could be a promising nanoparticle-based therapeutic approach for the treatment of hepatocellular carcinoma and shows potential for future clinical applications.

Citing Articles

Application of nanotechnology in the treatment of hepatocellular carcinoma.

Cai L, Du Y, Xiong H, Zheng H Front Pharmacol. 2024; 15:1438819.

PMID: 39679376 PMC: 11637861. DOI: 10.3389/fphar.2024.1438819.

Microwave ablation combined with transarterial chemoembolization containing doxorubicin hydrochloride liposome for treating primary and metastatic liver cancers.

Shi Q, Zhang Z, Zhang W, Ma J, Yang M, Luo J J Interv Med. 2023; 6(3):121-125.

PMID: 37846340 PMC: 10577058. DOI: 10.1016/j.jimed.2023.07.002.

Exploiting targeted nanomedicine for surveillance, diagnosis, and treatment of hepatocellular carcinoma.

Liu T, Liu L, Li L, Cai J Mater Today Bio. 2023; 22:100766.

PMID: 37636988 PMC: 10457457. DOI: 10.1016/j.mtbio.2023.100766.

PEGylated Liposomes Loaded with Carbamate Inhibitor ANP0903 Trigger Apoptosis by Enhancing ER Stress in HepG2 Cancer Cells.

Caddeo C, Miglionico R, Rinaldi R, Nigro I, Lamorte D, Chiummiento L Int J Mol Sci. 2023; 24(5).

PMID: 36901980 PMC: 10002784. DOI: 10.3390/ijms24054552.

Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes-A Preliminary Study.

Bartos A, Iancu I, Ciobanu L, Onaciu A, Moldovan C, Moldovan A Nanomaterials (Basel). 2022; 12(16).

PMID: 36014698 PMC: 9414144. DOI: 10.3390/nano12162833.

References

Huang L, Zhou K, Zhang J, Ma Y, Yang W, Ran L . Efficacy and safety of high-intensity focused ultrasound ablation for hepatocellular carcinoma by changing the acoustic environment: microbubble contrast agent (SonoVue) and transcatheter arterial chemoembolization. Int J Hyperthermia. 2019; 36(1):244-252. DOI: 10.1080/02656736.2018.1558290. View

Solazzo S, Ahmed M, Schor-Bardach R, Yang W, Girnun G, Rahmanuddin S . Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology. 2010; 255(1):62-74. PMC: 2843831. DOI: 10.1148/radiol.09091196. View

Wang Y, Huang H, Zou H, Tian X, Hu J, Qiu P . Liposome Encapsulation of Oncolytic Virus M1 To Reduce Immunogenicity and Immune Clearance in Vivo. Mol Pharm. 2019; 16(2):779-785. DOI: 10.1021/acs.molpharmaceut.8b01046. View

Johnson B, Wright G . Regional therapies for the treatment of primary and metastatic hepatic tumors: A disease-based review of techniques and critical appraisal of current evidence. Am J Surg. 2019; 217(3):541-545. DOI: 10.1016/j.amjsurg.2018.10.018. View

Dong H, Pang L, Cong H, Shen Y, Yu B . Application and design of esterase-responsive nanoparticles for cancer therapy. Drug Deliv. 2019; 26(1):416-432. PMC: 6450553. DOI: 10.1080/10717544.2019.1588424. View

Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant R, Torchilin V . Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: reduced tumor growth and increased animal endpoint survival in a small animal tumor model. J Control Release. 2012; 160(2):239-44. PMC: 3412588. DOI: 10.1016/j.jconrel.2011.12.031. View

Xu J, Cheng X, Tan L, Fu C, Ahmed M, Tian J . Microwave Responsive Nanoplatform via P-Selectin Mediated Drug Delivery for Treatment of Hepatocellular Carcinoma with Distant Metastasis. Nano Lett. 2019; 19(5):2914-2927. DOI: 10.1021/acs.nanolett.8b05202. View

Yang R, Hou M, Gao Y, Zhang L, Xu Z, Kang Y . Indocyanine green-modified hollow mesoporous Prussian blue nanoparticles loading doxorubicin for fluorescence-guided tri-modal combination therapy of cancer. Nanoscale. 2019; 11(12):5717-5731. DOI: 10.1039/c8nr10430a. View

Zhou Q, Wu S, Gong N, Li X, Dou J, Mu M . Liposomes loading sodium chloride as effective thermo-seeds for microwave ablation of hepatocellular carcinoma. Nanoscale. 2017; 9(31):11068-11076. DOI: 10.1039/c7nr02955a. View

10.

Yan F, Wang S, Yang W, Goldberg S, Wu H, Duan W . Tumor-penetrating Peptide-integrated Thermally Sensitive Liposomal Doxorubicin Enhances Efficacy of Radiofrequency Ablation in Liver Tumors. Radiology. 2017; 285(2):462-471. DOI: 10.1148/radiol.2017162405. View

11.

Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T . Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Can J Gastroenterol Hepatol. 2018; 2018:4756147. PMC: 6008833. DOI: 10.1155/2018/4756147. View

12.

Chen X, Fu C, Wang Y, Wu Q, Meng X, Xu K . Mitochondria-targeting nanoparticles for enhanced microwave ablation of cancer. Nanoscale. 2018; 10(33):15677-15685. DOI: 10.1039/c8nr03927e. View

13.

Deng Z, Yan F, Jin Q, Li F, Wu J, Liu X . Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound. J Control Release. 2013; 174:109-16. DOI: 10.1016/j.jconrel.2013.11.018. View

14.

Mu L, Sun L, Pan T, Lyu N, Li S, Li X . Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results. Int J Hyperthermia. 2017; 34(1):59-67. DOI: 10.1080/02656736.2017.1318332. View

15.

Costentin C . [Hepatocellular carcinoma surveillance]. Presse Med. 2017; 46(4):381-385. DOI: 10.1016/j.lpm.2016.11.006. View

16.

Jha S, Sharma P, Malviya R . Liposomal Drug Delivery System for Cancer Therapy: Advancement and Patents. Recent Pat Drug Deliv Formul. 2016; 10(3):177-183. DOI: 10.2174/1872211310666161004155757. View

17.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

18.

Fang Y, Li H, Yin H, Xu S, Ren W, Ding S . Radiofrequency-Sensitive Longitudinal Relaxation Tuning Strategy Enabling the Visualization of Radiofrequency Ablation Intensified by Magnetic Composite. ACS Appl Mater Interfaces. 2019; 11(12):11251-11261. DOI: 10.1021/acsami.9b02401. View

19.

Salati U, Barry A, Chou F, Ma R, Liu D . State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma. Future Oncol. 2017; 13(16):1437-1448. DOI: 10.2217/fon-2017-0061. View

20.

Chu K, Dupuy D . Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014; 14(3):199-208. DOI: 10.1038/nrc3672. View